Filing Flows › Glaukos (GKOS) › Q2 2026 › vs Q1 2026
Glaukos (GKOS) Q2 2026 vs Q1 2026 (quarter over quarter)
Glaukos's revenue rose $35.0M (+23%) from $151M in Q1 2026 to $186M in Q2 2026. The biggest changes: Glaucoma +$25.9M (+20%); Corneal Health +$9.1M (+43%).
Glaukos, Q2 2026: revenue $186M (+50% year over year), operating margin -9.3%, net loss $18.4M, operating cash flow $14.8M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 6.5% | -10.9% | +17.5 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Glaucoma | $155M | $129M | $25.9M | +20% |
| Corneal Health | $30.4M | $21.3M | $9.1M | +43% |
| Revenue | $186M | $151M | $35.0M | +23% |
| Net loss | $18.4M | $19.8M | −$1.4M | -7% |
| Costs & expenses | $204M | $171M | $33.1M | +19% |
| Operating costs | $203M | $170M | $32.5M | +19% |
| Income tax | $656K | $484K | $172K | +36% |
| Cost of revenue | $34.0M | $33.3M | $677K | +2% |
| Research & development | $51.3M | $44.1M | $7.2M | +16% |
| SG&A | $116M | $92.9M | $23.1M | +25% |
| Operating cash sources | $37.7M | $30.9M | $6.8M | +22% |
| Depreciation & amortization | $8.9M | $11.8M | −$2.9M | -25% |
| Share-based compensation | $28.9M | $19.1M | $9.7M | +51% |
| Net loss absorbed | $18.4M | $19.8M | −$1.4M | -7% |
| Working capital & other | $4.5M | $23.7M | −$19.1M | -81% |
| Operating cash flow | $14.8M | −$12.5M | $27.3M | — |
| Free cash flow (OCF − capex) | $12.1M | −$16.5M | $28.6M | — |
| Capital expenditures | $2.7M | $4.0M | −$1.2M | -31% |
Questions
How much did Glaukos's revenue grow quarter over quarter in Q2 2026?
Glaukos's revenue rose $35.0M (+23%) from $151M in Q1 2026 to $186M in Q2 2026.
What drove Glaukos's revenue change in Q2 2026?
Glaucoma +$25.9M (+20%); Corneal Health +$9.1M (+43%).